Revumenib
About
Therapy type: Targeted therapy
Therapy strategy: Menin inhibition
Mappings
NCI Thesaurus: Revumenib (ncit:C165776)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | t(KMT2A;v) | Acute Lymphoid Leukemia | Revumenib | FDA |
| Sensitivity (+) | t(KMT2A;v) | Acute Myeloid Leukemia | Revumenib | FDA |
| Sensitivity (+) | t(KMT2A;v) | Burkitt Lymphoma | Revumenib | FDA |
| Sensitivity (+) | t(KMT2A;v) | Acute Leukemias of Ambiguous Lineage | Revumenib | FDA |
| Sensitivity (+) | NPM1 p.W288Cfs*12 | Acute Myeloid Leukemia | Revumenib | FDA |
| Sensitivity (+) | NPM1 p.W288Cfs*12 | Acute Lymphoid Leukemia | Revumenib | FDA |
| Sensitivity (+) | NPM1 p.W288Cfs*12 | Burkitt Lymphoma | Revumenib | FDA |
| Sensitivity (+) | NPM1 p.W288Cfs*12 | Acute Leukemias of Ambiguous Lineage | Revumenib | FDA |